Search
Search
Learn about the enhancements to our comprehensive suite of workflows designed to transform and streamline the analysis of biotherapeutics. Discover cutting-edge advancements in biotherapeutic characterization and explore the newest tools in the Thermo Scientific BioPharma Finder software, version 5.3. Gain insights into how these advancements can transform your analysis process and learn how connecting BioPharma Finder to the Thermo Scientific Ardia Platform enables secure data sharing, seamless data processing and reporting, for more efficient and insightful analysis.
In the second part of this webinar, we will delve into a case study presented by the National Institute for Bioprocessing Research and Training (NIBRT) and explore how the Ardia Platform enabled scientists at NIBRT to deliver comparability studies for biosimilarity assessment, simplifying peptide mapping data analysis and method development activities. Bring your questions and discuss with experienced users how they studied characterization of post-translational modifications of the Trastuzumab originator against commercially available biosimilar products.
Learning objectives
Roberto Gamez, Product Manager, Thermo Fisher Scientific
Roberto Gamez is a Product Manager focusing primarily on the Thermo Scientific BioPharma Finder software platform. Previously, he was a Senior Field Applications Scientist focused on supporting biopharmaceutical characterization applications using Orbitrap instruments. Roberto has extensive experience with mass spectrometry and earned his Ph.D. at Texas A&M University in the Russell lab developing approaches for native MS analysis of protein assemblies.
Dr. Sara Carillo, Ph.D.
Bioanalytical Research Lead at the Characterisation and Comparability Laboratory, National Institute for Bioprocessing Research and Training (NIBRT), Dublin, Ireland
Dr. Sara Carillo completed her Ph.D. in Chemical Sciences in 2013 at the University of Naples “Federico II” focusing on the structural characterization of polysaccharides and glycoconjugates from Gram-negative bacteria via NMR and mass spectrometry techniques. In 2015 she joined Dr. Jonathan Bones group in NIBRT working on the understanding of the effects of extractables and leachables from single-use bioreactors on CHO cells N-glycome and produced monoclonal antibodies. She is now working in NIBRT as Bioanalytical Research Lead and is mainly interested in the development of new mass spectrometry-based analytical approaches to ensure deeper and easier understanding of biomanufacturing process and biopharmaceuticals structural complexity.